To overcome production hurdles for cell and gene therapies, a promising new class of biologic medications, NJIT’s New Jersey Innovation Institute (NJII) has opened clinical-scale centers that will work directly with drug developers to streamline the processing of new therapies and manufacture them in large quantities. NJII’s new company, BioCentriq, was formed in collaboration with leaders in the pharmaceutical industry, top regulators at federal agencies that oversee biologic therapies and state economic development officials. It is the first such enterprise in the nation backed by a university. To read the full story.
Home / News / New Jersey Innovation Institute’s BioCentriq Aims to Usher in a New Era in Cell and Gene Therapies
Recent Posts
- NJIT Students Develop Mental Health Side-Effect Tracker Recognized at Pfizer Hackathon.
- Older Adults With HIV May Be Facing Unequal Burden in the Opioid Crisis.
- Rutgers Medical Students Learn Importance of Humanity, Creativity and Connection in Patient-Centered Medicine.
- Artificial Intelligence Recreates the Motion of a Beating Heart Using Surface Electrical Recordings.
- Scientists Discover Potential Blood Test for Asthma Diagnosis and Severity.
Categories
- Community (2,364)
- Covid (992)
- CTO Events (6)
- News (3,001)
- Pilots (21)